France In-Vitro Diagnostics Market will reach US$ 4.03 Billion in 2028, according to the publisher. In vitro, diagnostics is a medical method used to identify diseases, conditions, or infections by examining samples like blood, urine, and tissue to analyze their diseased states. These examinations are primarily conducted in independent laboratories, hospital-based facilities, clinical labs, and point-of-care centers to diagnose various illnesses. IVD tests encompass diverse technologies, including polymerase chain reaction, which selectively duplicates specific DNA and RNA sequences in a test tube. Additional techniques involve isolating particular proteins through protein purification, in vitro fertilization, microarray methods, and sequencing technology.France in-vitro Diagnostics Market was US$ 2.99 Billion in 2022
The In-Vitro Diagnostics market is a dynamic segment within the medical industry in France. Presently, the sector is experiencing notable transformations. However, with the country facing the escalating financial pressures of an aging population and a comprehensive national healthcare system, the necessity to harness efficient diagnostics' cost/benefit advantages is becoming increasingly evident within the industry.
France In-Vitro Diagnostics Market shall grow at a CAGR of 5.10% from 2022 to 2028
The growth of France in-vitro diagnostics market is because of factors such as the increasing prevalence of chronic diseases, growing awareness and acceptance of personalized medicine and companion diagnostics, and expanding utilization of point-of-care (POC) diagnostics. The rising burden of chronic illnesses like infectious diseases, cardiovascular diseases, cancers, and others is a significant driver for the demand in the market.For instance, according to IDF Atlas 10th edition, the number of individuals living with diabetes in France was around 3,942.9 thousand in 2021, projected to reach 4,184.9 thousand by 2030 and 4,225.7 thousand by 2045. Adopting point-of-care diagnostics in the country and initiatives to increase awareness and promote testing for chronic diseases also contribute to market growth. For instance, in March 2022, France launched a new colon-cancer testing system for individuals aged 50-74. Hence, the market value for France in-vitro Diagnostics Market was US$ 2.99 Billion in 2022.
There is a strong potential for substantial growth in the services segment of France in-vitro diagnostics market
France in-vitro diagnostics market comprises product segments such as Services, Instruments, and Reagents.The growth of services in the France IVD market can be due to the increasing complexity of diagnostics tests, the shift towards value-based healthcare, the emphasis on personalized medicine and companion diagnostics, the rising demand for point-of-care testing, and escalating prevalence of chronic diseases.Advancements in medical technology have led to sophisticated tests requiring specialized expertise. Outsourcing diagnostics services helps optimize resources and improve outcomes. Personalized medicine and companion diagnostics drive the need for advanced testing. Point-of-care testing offers quick results and enhanced patient care. In addition, the growing burden of chronic diseases necessitates testing, monitoring, and management services.
Rapid tests are becoming increasingly popular in France In-vitro Diagnostics market
France in-vitro diagnostics market provides a diverse range of test types, including ELISA & CLIA, PCR, Rapid Test, Fluorescence Immunoassays (FIA), In Situ Hybridization, Transcription Mediated Amplification, Sequencing, Colorimetric Immunoassay, Radioimmunoassay (RIA), Isothermal Nucleic Acid Amplification Technology, and various others. Rapid tests provide quick results and eliminate the need for laboratory processing. They are ideal for point-of-care applications, aiding prompt diagnosis and treatment.Rapid tests are vital in controlling infectious diseases, enabling early detection and infection control. They also contribute to screening programs for early intervention and preventive care. Technological advancements have improved rapid test performance, including enhanced accuracy and multiplex capabilities. The growing demand for efficient and cost-effective diagnostics has led to the widespread adoption of rapid tests across medical specialties and healthcare settings in France.
Infectious diseases application is thriving in France In-vitro Diagnostics market
France market for in-vitro diagnostics encompasses various essential applications, including Infectious Diseases, Diabetes, Cardiology, Oncology, Nephrology, Autoimmune Diseases, Drug Testing, and several others. Public health concerns and the high prevalence of infectious diseases drive the demand for accurate and timely diagnostics in France. Rapid and precise diagnosis is crucial for disease detection, treatment, and preventive measures.In addition, infectious disease diagnostics are vital during outbreaks and epidemics, guiding control measures and patient management. Regulatory support and initiatives further promote in-vitro diagnostics for infectious diseases. These factors contribute to the dominance of infectious disease diagnostics in the France IVD market.
Immunoassay is dominant in the France in-vitro diagnostics market due to its versatility, sensitivity, and extensive range of applications
France in-vitro diagnostics market utilizes various technologies, including Immunoassay, Clinical Chemistry, Molecular Diagnostics/Genetics, Hematology, Microbiology, Coagulation, and other related technologies. Immunoassay technology offers high versatility and sensitivity, making it suitable for various diagnostic applications. It has proven particularly effective in diagnosing infectious diseases, autoimmune disorders, cancer biomarkers, and hormone imbalances. The reliability and accuracy of immunoassay results, its widespread availability, and established validation protocols further contribute to its dominance in the French IVD market. Additionally, the continuous advancements in immunoassay technology and the availability of a diverse range of immunoassay kits and reagents drive its widespread adoption and market dominance.Hospitals continue to hold a dominant position in France In-vitro Diagnostics market
The end-users in France In-vitro diagnostics market consist of four categories: Hospitals, Laboratories, Home-Care, and Others. Hospitals are pivotal as primary healthcare centers, serving many patients requiring diagnostic tests. Their large testing volume, advanced infrastructure, and specialized facilities for complex procedures make hospitals the preferred choice for advanced testing.With access to diverse medical specialists and healthcare professionals, hospitals effectively interpret and utilize diagnostic results. Integrating laboratory services within hospitals enables seamless coordination between diagnostics and treatment decisions-these comprehensive capabilities and resources position hospitals as dominant end-users in the France in-vitro diagnostics market.
Key Players
Prominent companies in France in-vitro diagnostics market include Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific, Sysmex Corporation, and QIAGEN N.V.In November 2022: Roche Diagnostics introduced the BenchMark ULTRA PLUS system in France, a cutting-edge platform developed explicitly for staining histological or cytological samples on microscope slides. The system debuted at the prestigious Carrefour Pathologie 2022 event, which took place at the Palais des Congrès de la Porte Maillot in Paris.
The report titled “France’s in-vitro Diagnostics Market Global Forecast by products (Services, Instruments, and Reagents), Test types (ELISA & CLIA, PCR, Rapid Test, Fluorescence Immunoassays (FIA), In Situ Hybridization, Transcription Mediated Amplification, Sequencing, Colorimetric Immunoassay, Radioimmunoassay (RIA), Isothermal Nucleic Acid Amplification Technology, and Others), Application (Infectious Diseases, Diabetes, Cardiology, Oncology, Nephrology, Autoimmune Diseases, Drug Testing, and Others), Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics/Genetics, Hematology, Microbiology, Coagulation, and Others), End-Users (Hospitals, Laboratories, Home - Care, and Others), Company Analysis (Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific,Sysmex Corporation, and QIAGEN N.V)' provides a detailed analysis of France’s in-vitro Diagnostics Market.
Products - Market breakup from 3 Viewpoints:
1. Services2. Instruments
3. Reagents
Test Types - Market breakup from 11 Viewpoints:
1. ELISA & CLIA2. PCR
3. Rapid Test
4. Fluorescence Immunoassays (FIA)
5. In Situ Hybridization
6. Transcription Mediated Amplification
7. Sequencing
8. Colorimetric Immunoassay
9. Radioimmunoassay (RIA)
10. Isothermal Nucleic Acid Amplification Technology
11. Others
Application - Market breakup from 8 Viewpoints:
1. Infectious Diseases2. Diabetes
3. Cardiology
4. Oncology
5. Nephrology
6. Autoimmune Diseases
7. Drug Testing
8. Others
Technology - Market breakup from 7 Viewpoints:
1. Immunoassay2. Clinical Chemistry
3. Molecular Diagnostics/Genetics
4. Hematology
5. Microbiology
6. Coagulation
7. Others
End-Users - Market breakup from 4 Viewpoints:
1. Hospitals2. Laboratories
3. Home - Care
4. Others
Company has been covered from 3 Viewpoints:
- Overview
- Recent Development
- Revenue
Company Analysis:
1. Roche Diagnostics2. Abbott Diagnostics
3. Siemens Healthineers
4. Danaher Corporation
5. Thermo Fisher Scientific
6. Sysmex Corporation
7. QIAGEN N.V
Table of Contents
1. Introduction2. Research & Methodology3. Executive Summary7. France In-Vitro Diagnostics (IVD) Market14. Government Rules & Regulation
4. Market Dynamics
5. Porter’s Five Forces
6. SWOT Analysis
8. Market Share - France In-Vitro Diagnostics (IVD)
9. Test Types - France In-Vitro Diagnostics (IVD) Market
10. Technology - France In-Vitro Diagnostics (IVD) Market
11. Product Types - France In-Vitro Diagnostics (IVD) Market
12. Application - France In-Vitro Diagnostics (IVD) Market
13. End User - France In-Vitro Diagnostics (IVD) Market
15. Reimbursement
16. Company Analysis
List of Figures:
List of Tables:
Companies Mentioned
- Roche Diagnostics
- Abbott Diagnostics
- Siemens Healthineers
- Danaher Corporation
- Thermo Fisher Scientific
- Sysmex Corporation
- QIAGEN N.V
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 185 |
| Published | May 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 2.99 Billion |
| Forecasted Market Value ( USD | $ 4.03 Billion |
| Compound Annual Growth Rate | 5.1% |
| Regions Covered | France |
| No. of Companies Mentioned | 7 |
